RNA-binding Protein CELF6 Modulates Transcription and Splicing Levels of Genes Associated with Tumorigenesis in Lung Cancer A549 Cells

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 Aug 1

PMID 35910766

Authors

Husai Ma

Guowei Liu

Bin Yu

Joshua Wang

Yali Qi

Yiying Kou

Ying Hu

Shunjun Wang

Fei Wang

Dong Chen

Affiliations

Soon will be listed here.

Abstract

CELF6 (CUGBP Elav-Like Family Member 6), a canonical RNA binding protein (RBP), plays important roles in post-transcriptional regulation of pre-mRNAs. However, the underlying mechanism of lower expressed CELF6 in lung cancer tissues is still unclear. In this study, we increased CELF6 manually in lung cancer cell line (A549) and utilized transcriptome sequencing (RNA-seq) technology to screen out differentially expressed genes (DEGs) and alternative splicing events (ASEs) after CELF6 over-expression (CELF6-OE). We found that CELF6-OE induced 417 up-regulated and 1,351 down-regulated DEGs. Functional analysis of down-regulated DEGs showed that they were highly enriched in immune/inflammation response- related pathways and cell adhesion molecules (CAMs). We also found that CELF6 inhibited the expression of many immune-related genes, including TNFSF10, CCL5, JUNB, BIRC3, MLKL, PIK3R2, CCL20, STAT1, MYD88, and CFS1, which mainly promote tumorigenesis in lung cancer. The dysregulated DEGs were also validated by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) experiment. In addition, CELF6 regulates the splicing pattern of large number of genes that are enriched in p53 signaling pathway and apoptosis, including TP53 and CD44. In summary, we made an extensive analysis of the transcriptome profile of gene expression and alternative splicing by CELF6-OE, providing a global understanding of the target genes and underlying regulation mechanisms mediated by CELF6 in the pathogenesis and development of lung cancer.

Citing Articles

CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2.

Lai J, Li L, Liu J, Yan Q, Xu Z, Leng M Cardiovasc Toxicol. 2025; 25(3):441-454.

PMID: 40021568 DOI: 10.1007/s12012-024-09951-5.

Role of the RNA-binding protein family in gynecologic cancers.

Hao L, Zhang J, Liu Z, Zhang Z, Mao T, Guo J Am J Cancer Res. 2023; 13(8):3799-3821.

PMID: 37693158 PMC: 10492115.

Long noncoding RNA LINC01594 inhibits the CELF6-mediated splicing of oncogenic CD44 variants to promote colorectal cancer metastasis.

Liu B, Song A, Gui P, Wang J, Pan Y, Li C Cell Death Dis. 2023; 14(7):427.

PMID: 37452042 PMC: 10349055. DOI: 10.1038/s41419-023-05924-8.

References

Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M . The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem Biophys Res Commun. 2020; 524(1):150-155. DOI: 10.1016/j.bbrc.2020.01.042. View

Makrilia N, Kollias A, Manolopoulos L, Syrigos K . Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009; 27(10):1023-37. DOI: 10.3109/07357900902769749. View

Su C, Li Y, Han Y, Zhou S, Liu Z . Correlation between expression of cell adhesion molecules CD₄₄ v6 and E-cadherin and lymphatic metastasis in non- small cell lung cancer. Asian Pac J Cancer Prev. 2014; 15(5):2221-4. DOI: 10.7314/apjcp.2014.15.5.2221. View

Li W, Li N, Gao L, You C . Integrated analysis of the roles and prognostic value of RNA binding proteins in lung adenocarcinoma. PeerJ. 2020; 8:e8509. PMC: 7007976. DOI: 10.7717/peerj.8509. View

Hung J, Horn D, Woodruff K, Prihoda T, LeSaux C, Peters J . Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest. 2014; 94(4):371-81. DOI: 10.1038/labinvest.2014.1. View

Liu Z, Fu Q, Wang Y, Cui L, Zhang W, Teng Y . Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways. Biomed Pharmacother. 2020; 134:111144. DOI: 10.1016/j.biopha.2020.111144. View

Li W, Gao L, Song P, You C . Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. Aging (Albany NY). 2020; 12(4):3558-3573. PMC: 7066909. DOI: 10.18632/aging.102828. View

Wang S, Ma H, Li H, Liu Q, Huang S, Huang L . Alternatively Expressed Transcripts Analysis of Non-Small Cell Lung Cancer Cells under Different Hypoxic Microenvironment. J Oncol. 2021; 2021:5558304. PMC: 8055392. DOI: 10.1155/2021/5558304. View

Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R . New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. J Control Release. 2019; 295:250-267. DOI: 10.1016/j.jconrel.2019.01.009. View

10.

Liu Y, Qing H, Su X, Wang C, Li Z, Liu S . Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis. Med Sci Monit. 2015; 21:2694-700. PMC: 4573070. DOI: 10.12659/MSM.894357. View

11.

Xiao R, Chen J, Liang Z, Luo D, Chen G, Lu Z . Pervasive Chromatin-RNA Binding Protein Interactions Enable RNA-Based Regulation of Transcription. Cell. 2019; 178(1):107-121.e18. PMC: 6760001. DOI: 10.1016/j.cell.2019.06.001. View

12.

Liu G, Zhang Q, Xia L, Shi M, Cai J, Zhang H . RNA-binding protein CELF6 is cell cycle regulated and controls cancer cell proliferation by stabilizing p21. Cell Death Dis. 2019; 10(10):688. PMC: 6751195. DOI: 10.1038/s41419-019-1927-0. View

13.

Perez-Perri J, Noerenberg M, Kamel W, Lenz C, Mohammed S, Hentze M . Global analysis of RNA-binding protein dynamics by comparative and enhanced RNA interactome capture. Nat Protoc. 2020; 16(1):27-60. PMC: 7116560. DOI: 10.1038/s41596-020-00404-1. View

14.

Guo Y, Feng Y, Liu H, Luo S, Clarke J, Moorman P . Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial. Mol Carcinog. 2019; 58(7):1094-1104. PMC: 6548610. DOI: 10.1002/mc.23017. View

15.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

16.

Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S . KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011; 39(Web Server issue):W316-22. PMC: 3125809. DOI: 10.1093/nar/gkr483. View

17.

Shinohara S, Hanagiri T, Taira A, Takenaka M, Oka S, Chikaishi Y . Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer. Oncology. 2016; 90(6):327-38. DOI: 10.1159/000445951. View

18.

Qin K, Hou H, Liang Y, Zhang X . Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer. 2020; 20(1):328. PMC: 7164297. DOI: 10.1186/s12885-020-06805-5. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V . Concomitant Mutation Confers Worse Prognosis in -Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. J Clin Med. 2020; 9(4). PMC: 7230306. DOI: 10.3390/jcm9041047. View